Efficacy of novel selective NLRP3 inhibitors in human and murine retinal pigment epithelial cells
- 933 Downloads
NLRP3 inflammasome activation in the retinal pigment epithelium (RPE) is observed in atrophic age-related macular degeneration (AMD), and pharmacological NLRP3 inhibition may provide a therapeutic strategy to halt disease progression. We tested selective NLRP3 inhibitors (IFM-514, IFM-632, and CRID3) for their efficacy in human and murine RPE cells. Inflammasome activation was induced in primary human RPE cells and ARPE-19 cells following priming with IL-1α by different stimuli, including lysosomal membrane permeabilization by leucyl-leucine methyl ester (Leu-Leu-OMe), oxidative damage induced by hydrogen peroxide, lipofuscin-mediated photooxidative damage induced by incubation with 4-hydroxynonenal-modified photoreceptor outer segments and subsequent blue light irradiation, and P2X7 receptor activation by benzoylbenzoyl-ATP. Independent of the applied activation mechanism, treatment with the NLRP3 inhibitors IFM-632, IFM-514, and CRID3 resulted in a significant suppression of inflammasome activation as assessed by IL-1β and LDH release. Likewise, inflammasome activation in blue light-irradiated Abca4−/− mouse and Leu-Leu-OMe-treated wild-type mouse RPE/choroid/sclera eye cups was significantly reduced by treatment with the NLRP3 inhibitors. These results indicate that the investigated selective NLRP3 inhibitors are effective in human and murine RPE cells, thus representing promising agents for the future evaluation of inflammasome inhibition as a therapeutic strategy in atrophic AMD.
• NLRP3 inhibitors suppress inflammasome activation in human RPE cells independent of trigger.
• Light-induced inflammasome activation in Abca4−/− mouse eye cups is reduced by NLRP3 inhibitors.
• Novel selective NLRP3 inhibitors are effective in human and murine RPE cells.
• Promising compounds for pharmaceutical intervention in atrophic AMD.
KeywordsAge-related macular degeneration Interleukin-1 Lysosomal membrane permeabilization Oxidative damage P2X7 receptor
NLRP3 inhibitors IFM-632 and IFM-514 were kindly provided by IFM Therapeutics (Boston, Massachusetts, USA). Abca4−/− mice were a kind gift from Alun Barnard (University of Oxford, Oxford, UK).
This work was supported by the China Scholarship Council (CSC; to L.W.), Ernst and Berta Grimmke Foundation (to P.P.L. and T.U.K.), German Research Foundation (DFG; grant KR 2863/7-2 to T.U.K., collaborative research centers SFB/TRR57 and SFB/TRR83), Volker Homann Foundation (to T.U.K.), Dr. Eberhard und Hilde Rüdiger Foundation (to T.U.K.), and the European Research Council (ERC) grant InflammAct (to E.L.).
Compliance with ethical standards
Conflict of interest
L. Wang, S. Schmidt, P. P. Larsen declare that they have no conflict of interest. J. H. Meyer declares support from Heidelberg Engineering. W. R. Roush is a shareholder and employee of IFM Therapeutics. E. Latz is a co-founder and consultant of IFM Therapeutics. F. G. Holz declares support from Acucela, Allergan, Bayer, Centervue, NightstarX, Novartis, Genentech/Roche, Heidelberg Engineering, Optos, and Carl Zeiss Meditec. T. U. Krohne declares support from Alimera Sciences, Bayer, Heidelberg Engineering, and Novartis.
- 1.European Society of Retina Specialists (EURETINA) (2017) Retinal diseases in Europe: prevalence, incidence and healthcare needs. Available online at http://www.euretina.org/downloads/EURETINA_Retinal_Diseases.pdf. Accessed 31 Aug 2018
- 3.Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S et al (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149:847–859Google Scholar
- 4.Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC et al (2012) NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18:791–798Google Scholar
- 5.Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D’Amore PA, Ksander BR (2013) NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 54:110–120Google Scholar
- 6.Cao S, Wang JC, Gao J, Wong M, To E, White VA, Cui JZ, Matsubara JA (2016) CFH Y402H polymorphism and the complement activation product C5a: effects on NF-κB activation and inflammasome gene regulation. Br J Ophthalmol 100:713–718Google Scholar
- 7.Ijima R, Kaneko H, Ye F, Nagasaka Y, Takayama K, Kataoka K, Kachi S, Iwase T, Terasaki H (2014) Interleukin-18 induces retinal pigment epithelium degeneration in mice. Invest Ophthalmol Vis Sci 55:6673–6678Google Scholar
- 8.Budiene B, Liutkeviciene R, Gustiene O, Ugenskiene R, Laukaitiene D, Savukaityte A, Vilkeviciute A, Steponaviciute R, Rocyte A, Zaliuniene D (2018) The association of matrix metalloproteinases polymorphisms and interleukins in advanced age-related macular degeneration. Ophthalmic Genet 39:463–472Google Scholar
- 9.Zhao M, Bai Y, Xie W, Shi X, Li F, Yang F, Sun Y, Huang L, Li X (2015) Interleukin-1β level is increased in vitreous of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). PLoS One 10:1–10Google Scholar
- 10.Gao J, Cui JZ, To E, Cao S, Matsubara JA (2018) Evidence for the activation of pyroptotic and apoptotic pathways in RPE cells associated with NLRP3 inflammasome in the rodent eye. J Neuroinflammation 15:15Google Scholar
- 15.Karmakar M, Katsnelson M, Malak HA, Greene NG, Howell SJ, Hise AG, Camilli A, Kadioglu A, Dubyak GR, Pearlman E (2018) Neutrophil IL-1 β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol 194:1763–1775Google Scholar
- 16.Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ, Matsubara JA (2015) Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res 127:49–58Google Scholar
- 19.IFM Therapeutics (2017) Compounds and compositions for treating conditions associated with NLRP activity. World Intellectual Property Organization (WIPO), Geneva, Switzerland; publication number WO/2017/184624. Available online at https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017184624. Accessed 31 Aug 2018
- 20.Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248–255Google Scholar
- 21.Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L et al (2018) Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary. Inflammation 773:2421–2433Google Scholar
- 22.Krohne TU, Stratmann NK, Kopitz J, Holz FG (2010) Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 90:465–471Google Scholar
- 23.Krohne TU, Kaemmerer E, Holz FG (2010) Lipid peroxidation products reduce lysosomal protease activities in human retinal pigment epithelial cells via two different mechanisms of action. Exp Eye Res 90:261–266Google Scholar
- 24.Charbel Issa P, Barnard AR, Singh MS, Carter E, Jiang Z, Radu RA, Schraermeyer U, MacLaren RE (2013) Fundus autofluorescence in the Abca4 −/− mouse model of Stargardt disease—correlation with accumulation of A2E, retinal function, and histology. Invest Ophthalmol Vis Sci 54:5602–5612Google Scholar
- 26.Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P et al (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233–236Google Scholar
- 27.Mohr LK, Hoffmann AV, Brandstetter C, Holz FG, Krohne TU (2015) Effects of inflammasome activation on secretion of inflammatory cytokines and vascular endothelial growth factor by retinal pigment epithelial cells. Investig Opthalmol Vis Sci 56:6404Google Scholar
- 30.Guha S, Baltazar GC, Coffey EE, Tu LA, Lim JC, Beckel JM, Patel S, Eysteinsson T, Lu W, O’Brien-Jenkins A et al (2013) Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor. FASEB J 27:4500–4509Google Scholar
- 32.Ludwig-portugall I, Bartok E, Dhana E, Evers BD, Primiano MJ, Hall JP, Franklin BS, Knolle PA, Hornung V, Hartmann G et al (2016) An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int 90:525–539Google Scholar
- 33.Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O’Neill LAJ, Lynch MA (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun 61:306–316CrossRefPubMedGoogle Scholar
- 34.Zhou R, Yazdi AS, Menu P (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221–225Google Scholar
- 36.Arulkumaran N, Unwin RJ, Tam FWK (2011) A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 20:897–915Google Scholar
- 37.Di Virgilio F, Ben DD, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47:15–31Google Scholar
- 38.Kerur N, Hirano Y, Tarallo V, Fowler BJ, Bastos-Carvalho A, Yasuma T, Yasuma R, Kim Y, Hinton DR, Kirschning CJ et al (2013) TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci 54:3–9Google Scholar
- 39.Notomi S, Hisatomi T, Murakami Y, Terasaki H, Sonoda S, Asato R, Takeda A, Ikeda Y, Enaida H, Sakamoto T et al (2013) Dynamic increase in extracellular ATP accelerates photoreceptor cell apoptosis via ligation of P2RX7 in subretinal hemorrhage. PLoS One 8:e53338Google Scholar